These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 32164382)

  • 1. Efficacy of Divinylbenzenic Resin in Removing Indoxyl Sulfate and P-Cresol Sulfate in Hemodialysis Patients: Results From an In Vitro Study and An In Vivo Pilot Trial (xuanro4-Nature 3.2).
    Rocchetti MT; Cosola C; di Bari I; Magnani S; Galleggiante V; Scandiffio L; Dalfino G; Netti GS; Atti M; Corciulo R; Gesualdo L
    Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32164382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Bennis Y; Cluet Y; Titeca-Beauport D; El Esper N; Ureña P; Bodeau S; Combe C; Dussol B; Fouque D; Choukroun G; Liabeuf S
    Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31109001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can curcumin supplementation reduce plasma levels of gut-derived uremic toxins in hemodialysis patients? A pilot randomized, double-blind, controlled study.
    Salarolli RT; Alvarenga L; Cardozo LFMF; Teixeira KTR; de S G Moreira L; Lima JD; Rodrigues SD; Nakao LS; Fouque D; Mafra D
    Int Urol Nephrol; 2021 Jun; 53(6):1231-1238. PubMed ID: 33438085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial.
    Rossi M; Johnson DW; Morrison M; Pascoe EM; Coombes JS; Forbes JM; Szeto CC; McWhinney BC; Ungerer JP; Campbell KL
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):223-31. PubMed ID: 26772193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Removal of Protein-Bound Uremic Toxins during Hemodialysis Using a Binding Competitor.
    Madero M; Cano KB; Campos I; Tao X; Maheshwari V; Brown J; Cornejo B; Handelman G; Thijssen S; Kotanko P
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):394-402. PubMed ID: 30755453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbiome perturbation by oral vancomycin reduces plasma concentration of two gut-derived uremic solutes, indoxyl sulfate and p-cresyl sulfate, in end-stage renal disease.
    Nazzal L; Roberts J; Singh P; Jhawar S; Matalon A; Gao Z; Holzman R; Liebes L; Blaser MJ; Lowenstein J
    Nephrol Dial Transplant; 2017 Nov; 32(11):1809-1817. PubMed ID: 28379433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Removal of protein-bound, hydrophobic uremic toxins by a combined fractionated plasma separation and adsorption technique.
    Brettschneider F; Tölle M; von der Giet M; Passlick-Deetjen J; Steppan S; Peter M; Jankowski V; Krause A; Kühne S; Zidek W; Jankowski J
    Artif Organs; 2013 Apr; 37(4):409-16. PubMed ID: 23330821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adsorption of Protein-Bound Uremic Toxins Through Direct Hemoperfusion With Hexadecyl-Immobilized Cellulose Beads in Patients Undergoing Hemodialysis.
    Yamamoto S; Sato M; Sato Y; Wakamatsu T; Takahashi Y; Iguchi A; Omori K; Suzuki Y; Ei I; Kaneko Y; Goto S; Kazama JJ; Gejyo F; Narita I
    Artif Organs; 2018 Jan; 42(1):88-93. PubMed ID: 28703401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure.
    Lin CJ; Wu V; Wu PC; Wu CJ
    PLoS One; 2015; 10(7):e0132589. PubMed ID: 26173073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Innovative Synbiotic Formulation Decreases Free Serum Indoxyl Sulfate, Small Intestine Permeability and Ameliorates Gastrointestinal Symptoms in a Randomized Pilot Trial in Stage IIIb-IV CKD Patients.
    Cosola C; Rocchetti MT; di Bari I; Acquaviva PM; Maranzano V; Corciulo S; Di Ciaula A; Di Palo DM; La Forgia FM; Fontana S; De Angelis M; Portincasa P; Gesualdo L
    Toxins (Basel); 2021 May; 13(5):. PubMed ID: 34063068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients.
    Meijers BK; De Loor H; Bammens B; Verbeke K; Vanrenterghem Y; Evenepoel P
    Clin J Am Soc Nephrol; 2009 Dec; 4(12):1932-8. PubMed ID: 19833905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal-related uremic toxins in peritoneal dialysis: a pilot study with a 5-year follow-up.
    Lin CJ; Pan CF; Chuang CK; Liu HL; Sun FJ; Wang TJ; Chen HH; Wu CJ
    Arch Med Res; 2013 Oct; 44(7):535-41. PubMed ID: 24055267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LC-MS/MS method for simultaneous determination of serum p-cresyl sulfate and indoxyl sulfate in patients undergoing peritoneal dialysis.
    Shu C; Chen X; Xia T; Zhang F; Gao S; Chen W
    Biomed Chromatogr; 2016 Nov; 30(11):1782-1788. PubMed ID: 27129599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of uremic toxins and inflammation in hemodialysis patients.
    Hsu HJ; Yen CH; Wu IW; Hsu KH; Chen CK; Sun CY; Chou CC; Chen CY; Tsai CJ; Wu MS; Lee CC
    PLoS One; 2014; 9(7):e102691. PubMed ID: 25051062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sucroferric oxyhydroxide on gastrointestinal microbiome and uremic toxins in patients with chronic kidney disease undergoing hemodialysis.
    Iguchi A; Yamamoto S; Oda A; Tanaka K; Kazama JJ; Saeki T; Yamazaki H; Ishioka K; Suzutani T; Narita I
    Clin Exp Nephrol; 2020 Aug; 24(8):725-733. PubMed ID: 32285213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis.
    Deltombe O; Van Biesen W; Glorieux G; Massy Z; Dhondt A; Eloot S
    Toxins (Basel); 2015 Sep; 7(10):3933-46. PubMed ID: 26426048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indoxyl sulfate, not P-cresyl sulfate, is associated with advanced glycation end products in patients on long-term hemodialysis.
    Lin CJ; Lin J; Pan CF; Chuang CK; Liu HL; Sun FJ; Wang TJ; Chen HH; Wu CJ
    Kidney Blood Press Res; 2015; 40(2):121-9. PubMed ID: 25833743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary protein-fiber ratio associates with circulating levels of indoxyl sulfate and p-cresyl sulfate in chronic kidney disease patients.
    Rossi M; Johnson DW; Xu H; Carrero JJ; Pascoe E; French C; Campbell KL
    Nutr Metab Cardiovasc Dis; 2015 Sep; 25(9):860-865. PubMed ID: 26026209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in Dialysis Efficacy Have Limited Effects on Protein-Bound Uremic Toxins Plasma Levels over Time.
    Krieter DH; Kerwagen S; Rüth M; Lemke HD; Wanner C
    Toxins (Basel); 2019 Jan; 11(1):. PubMed ID: 30654454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function.
    Viaene L; Meijers BK; Bammens B; Vanrenterghem Y; Evenepoel P
    Perit Dial Int; 2014; 34(1):71-8. PubMed ID: 24179107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.